Cuijuan Zhang

Title: Innovations of Cuijuan Zhang in Monoclonal Antibodies

Introduction

Cuijuan Zhang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on creating low immunogenic human anti-TNF-α antibodies, which have important applications in biotherapy.

Latest Patents

Cuijuan Zhang holds a patent for "Anti-TNF-α fully human monoclonal antibodies with low immunogenicity and application thereof." This invention discloses low immunogenic human anti-TNF-α antibodies that can inhibit the apoptosis of cells induced by TNF-α. The antibodies bind specifically to TNF-α with affinities similar to Adalimumab. Most importantly, these antibodies exhibit reduced immunogenicities in vivo, making them safer candidates for antibody drugs and other biotherapies. The invention also includes methods for de-immunogenicity of antibody drugs by identifying and replacing high immunogenic FR sequences with low immunogenic sequences from other human IgGs, significantly reducing the risk of human anti-human immunogenicity and improving the efficacy of antibody drugs. Cuijuan Zhang has 1 patent to his name.

Career Highlights

Cuijuan Zhang is associated with Abmax Biotechnology Co., Ltd., where he continues to innovate in the field of biotechnology. His work has garnered attention for its potential to improve therapeutic options for patients.

Collaborations

Cuijuan Zhang collaborates with notable colleagues, including Le Sun and Xiaogang Zhang, who contribute to his research and development efforts.

Conclusion

Cuijuan Zhang's innovative work in the development of low immunogenic human anti-TNF-α antibodies represents a significant advancement in biotechnology. His contributions have the potential to enhance the safety and efficacy of antibody-based therapies.